Mayo Clinic - AuthorCitation

Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis

Weymann, Alexander , Sabashnikov, Anton , Popov, Aron-Frederik, Mirhosseini, Seyed Jalil , Liu, Tong , Lotfaliani, Mohammadreza , Sá, Michel Pompeu , Yavuz, Şenol , Zeriouh, Mohamed, Dehghan, Hamidreza , Meng, Lei , Testa, Luca , Benedetto, Umberto , Tse, Gary , Nombela‐Franco, Luis , Dohmen, Pascal M., Deshmukh, Abhishek , Stone, Gregg W. , Calkins, Hugh , [IMCSC-Group], Integrated Meta-Analysis of Cardiac Surgery and Cardiology-Group, Ali‐Hasan‐Al‐Saegh, Sadeq , Baker, William L. , Jang, Jae‐Sik , D’Ascenzo, Fabrizio , Linde, Cecilia , Biondi‐Zoccai, Giuseppe , [IMCSC-Group], Integrated Meta-Analysis of Cardiac Surgery and Cardiology-Group, Nombela-Franco, Luis , Sá, Michel Pompeu

Medical Science Monitor Basic Research | May 12, 2017 | Volume: 23 | Issue: No issue available | Pages: 179-222

Quantitation of valve regurgitation severity by three‐dimensional vena contracta area is superior to flow convergence method of quantitation on transesophageal echocardiography

Abudiab, Muaz M. , Naqvi, Tasneem Z. , Liu, Shuang , Naqvi, Tasneem Z , Chao, Chieh‐Ju , Liu, Shuang

Echocardiography | May 8, 2017 | Volume: 34 | Issue: 7 | Pages: 992-1001

BackgroundQuantitation of regurgitation severity using the proximal isovelocity acceleration (PISA) method to calculate effective regurgitant orifice (ERO) area has limitations. Measurement of three‐dimensional (3D) vena contracta area (VCA) accurately grades mitral regurgitation (MR) severity on transthoracic echocardiography (TTE).MethodsWe evaluated 3D VCA quantitation of regurgitant jet severity using 3D transesophageal echocardiography (TEE) in 110 native mitral, aortic, and tricuspid valves and six prosthetic valves in patients with at least mild valvular regurgitation. The ASE‐recommended integrative method comprising semiquantitative and quantitative assessment of valvular regurgitation was used as a reference method, including ERO area by 2D PISA for assigning severity of regurgitation grade.ResultsMean age was 62.2±14.4 years; 3D VCA quantitation was feasible in 91% regurgitant valves compared to 78% by the PISA method. When both methods were feasible and in the presence of a single regurgitant jet, 3D VCA and 2D PISA were similar in differentiating assigned severity (ANOVAP<.001). In valves with multiple jets, however, 3D VCA had a better correlation to assigned severity (ANOVAP<.0001). The agreement of 2D PISA and 3D VCA with the integrative method was 47% and 58% for moderate and 65% and 88% for severe regurgitation, respectively.ConclusionMeasurement of 3D VCA by TEE is superior to the 2D PISA method in determination of regurgitation severity in multiple native and prosthetic valves.

Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma

Zhao, Xiangxuan , Puszyk, William, Wallet, Shannon M. , Hochwald, Steve, Robertson, Keith D. , Liu, Chen , Robertson, Keith, Sun, Wei , Robertson, Keith D , Liu, Chen

Tumor Biology | May 1, 2017 | Volume: 39 | Issue: 5 | Pages: 101042831769912

10.1177/1010428317699120 | PMID 28459212

Pancreatic cancer has one of the lowest survival rates of all cancers. The mechanism underlying chemo-resistance of pancreatic cancer is not well understood. Our previous article reported that small molecule YM155 induced apoptosis in pancreatic cancer cells via activation of death receptor 5. In this study, we aim to continuously address death receptor 5–mediated apoptosis in chemo-resistant pancreatic carcinoma. We found that in comparison to paired pancreatic cancer tissues and adjacent normal tissues, five of the six cancer tissues had downregulated death receptor 5 and upregulated Bcl-xL. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. Interestingly, pre-treatment with Bcl-xL inhibitor ABT263 reversed the insensitivity of panc-1 cells to lexatumumab or PF573228-induced apoptosis. Specific small interfering RNA-mediated gene silencing of Bcl-xL effectively sensitized pancreatic cancer cells to lexatumumab or PF573228-induced apoptosis. Furthermore, lexatumumab and PF573228 combination was shown to exhibit significant xenograft pancreatic tumor growth inhibition in SCID mice. Our data provide fundamental evidence to support the notion that lexatumumab and PF573228 co-treatment could be a potentially effective regime for patients with pancreatic cancer.

A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

Perentesis, John P. , Liu, Xiaowei , Kudgus, Rachel A. , Fox, Elizabeth , Blaney, Susan M. , Weigel, Brenda J. , Reid, Joel M. , Geller, James I. , Minard, Charles G.

Pediatric Blood & Cancer | April 27, 2017 | Volume: 64 | Issue: 11 | Pages: No page available

10.1002/pbc.26565 | PMID 28449393

AbstractBackgroundThe c‐Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c‐Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.MethodsOral tivantinib capsules were administered twice daily with food, continuously in 28‐day cycles. Dose levels 170, 200, and 240 mg/m2/dose were evaluated using a rolling‐six design (Part A). In Part B, subjects received tivantinib powder sprinkled on food at the recommended phase 2 dose (RP2D) from Part A. PK, CYP2C19 genotyping, and baseline tumor tissue c‐Met expression were analyzed.ResultsThirty‐six patients were enrolled: 20 in Part A, 6 in a PK expansion cohort, and 10 in Part B. Fifteen patients had primary central nervous system tumors and 21 had solid tumors. In Part A, there were no dose‐limiting toxicities. One grade 4 intracranial hemorrhage occurred in a patient with a progressive brain tumor in the expanded PK cohort (240 mg/m2). PK analysis showed marked interpatient variability (20‐fold) in the Cmax and AUC0‐8h across all dose levels. Sprinkling tivantinib powder over food did not alter exposure. Membranous and total c‐Met expression was moderate (2), low (4), or not detected (26). Two patients had stable disease as the best response.ConclusionsThe RP2D of tivantinib given with food in children with refractory solid tumors is 240 mg/m2/dose. PK of tivantinib in children demonstrated high variability. Objective responses were not observed in this phase 1 trial.

Serologic Testing for Zika Virus: Comparison of Three Zika Virus IgM-Screening Enzyme-Linked Immunosorbent Assays and Initial Laboratory Experiences

Granger, Dane, Hilgart, Heather, Misner, Lori, Christensen, Jaime, Bistodeau, Sarah, Palm, Jennifer, Strain, Anna K., Konstantinovski, Marja, Liu, Dakai , Tran, Anthony, Theel, Elitza S.

Journal of Clinical Microbiology | April 27, 2017 | Volume: 55 | Issue: 7 | Pages: 2127-2136

10.1128/jcm.00580-17 | PMID 28446573

ABSTRACT Serologic evaluation for Zika virus (ZIKV) infection currently includes an initial screen using an anti-ZIKV IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) followed by supplemental testing of specimens with nonnegative results by a plaque reduction neutralization test (PRNT). We compared the performance characteristics of three ELISAs for the detection of IgM class antibodies to ZIKV, including the Centers for Disease Control and Prevention (CDC) Zika MAC-ELISA, the InBios ZIKV Detect MAC-ELISA, and the Euroimmun anti-Zika Virus IgM ELISA. Additionally, we present our initial experiences with ZIKV serologic testing from a national reference laboratory perspective. Using both retrospectively and prospectively collected specimens from patients with possible ZIKV infection, we show that the CDC and InBios MAC-ELISAs perform comparably to each other, with positive agreement, negative agreement, and interrater kappa values ranging from 87.5% to 93.1%, 95.7% to 98.5%, and 0.52 to 0.83, respectively. In contrast, comparison of the Euroimmun ZIKV ELISA to either the CDC or InBios MAC-ELISAs resulted in positive agreement, negative agreement, and interrater kappa values ranging from 17.9% to 42.9%, 91.7% to 98.6%, and 0.10 to 0.39, respectively. Among the 19 prospective samples submitted for PRNT, nine were negative, eight specimens had neutralizing antibodies to a flavivirus (unable to be identified), and one sample each was confirmed for ZIKV or dengue virus infection. This study highlights the ongoing challenges associated with serologic diagnosis of ZIKV infection. Although the availability of a commercial serologic test for ZIKV has greatly expanded the national capacity for such testing, the need to further characterize and improve these assays, particularly with regard to specificity, remains.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

LaPlant, Betsy, Call, Timothy G. , Leis, José F., He, Rong , Wiseman, Gregory A., Lin, Yi , Asmus, Erik, Nowakowski, Grzegorz S. , Conte, Michael, Bowen, Deborah A., Aitken, Casey N., Dyke, Daniel L. Van , Greipp, Patricia T. , Wu, Xiaosheng , Secreto, Charla, Tian, Shulan , Braggio, Esteban , Wellik, Linda, Micallef, Ivana N. , Viswanatha, David S., Yan, Huihuang , Chanan‐Khan, Asher , Ansell, Stephen M. , LaPlant, Betsy R, Chanan-Khan, Asher A., Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D. , Sinha, Sutapa , Le‐Rademacher, Jennifer , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Liu, Xin , Zhang, Henan , Kay, Neil E. , Dong, Haidong , Braggio, Esteban , Greipp, Patricia T , Lin, Yi

Blood | April 20, 2017 | Volume: 129 | Issue: 26 | Pages: 3419-3427

10.1182/blood-2017-02-765685 | PMID 28424162

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.

A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer

Shen, Jianliang , Kim, Han-Cheon, Wolfram, Joy , Mu, Chaofeng , Zhang, Wei , Xie, Yan , Li, Zhi , Mao, Zong‐Wan , Shen, Haifa , Xie, Yan , Mao, Zong-Wan , Liu, Haoran , Mai, Junhua , Zhang, Hang , Guevara, María L. , Wolfram, Joy

Nano Letters | April 18, 2017 | Volume: 17 | Issue: 5 | Pages: 2913-2920

10.1021/acs.nanolett.7b00132 | PMID 28418672

Functionalized Carbon Nanotube and Graphene Oxide Embedded Electrically Conductive Hydrogel Synergistically Stimulates Nerve Cell Differentiation

Liu, Xifeng , Park, Sungjo , Waletzki, Brian E., Zhou, Zifei , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee , Terzic, André

ACS Applied Materials & Interfaces | April 13, 2017 | Volume: 9 | Issue: 17 | Pages: 14677-14690

10.1021/acsami.7b02072 | PMID 28406608

Thibodeau, Stephen N. , Liu, Wanguo

The Japanese Journal of Urology | April 6, 2017 | Volume: 91 | Issue: 3 | Pages: 308

10.5980/jpnjurol.91.308_2

Application of a Natural Language Processing Algorithm to Asthma Ascertainment. An Automated Chart Review

Sohn, Sunghwan , Rolfes, Mary , Seabright, Alicia, Ryu, Euijung , Voge, Gretchen A., Bachman, Kay, Park, Miguel A., Kita, Hirohito , Croghan, Ivana T. , Liu, Hongfang , Juhn, Young J. , Bachman, Kay A, Wi, Chung‐Il , Kita, H

American Journal of Respiratory and Critical Care Medicine | April 4, 2017 | Volume: 196 | Issue: 4 | Pages: 430-437

10.1164/rccm.201610-2006oc | PMID 28375665

Abstract Rationale Difficulty of asthma ascertainment and its associated methodologic heterogeneity have created significant barriers to asthma care and research. Objectives We evaluated the validity of an existing natural language processing (NLP) algorithm for asthma criteria to enable an automated chart review using electronic medical records (EMRs). Methods The study was designed as a retrospective birth cohort study using a random sample of 500 subjects from the 1997–2007 Mayo Birth Cohort who were born at Mayo Clinic and enrolled in primary pediatric care at Mayo Clinic Rochester. Performance of NLP-based asthma ascertainment using predetermined asthma criteria was assessed by determining both criterion validity (chart review of EMRs by abstractor as a gold standard) and construct validity (association with known risk factors for asthma, such as allergic rhinitis). Measurements and Main Results After excluding three subjects whose respiratory symptoms could be attributed to other conditions (e.g., tracheomalacia), among the remaining eligible 497 subjects, 51% were male, 77% white persons, and the median age at last follow-up date was 11.5 years. The asthma prevalence was 31% in the study cohort. Sensitivity, specificity, positive predictive value, and negative predictive value for NLP algorithm in predicting asthma status were 97%, 95%, 90%, and 98%, respectively. The risk factors for asthma (e.g., allergic rhinitis) that were identified either by NLP or the abstractor were the same. Conclusions Asthma ascertainment through NLP should be considered in the era of EMRs because it can enable large-scale clinical studies in a more time-efficient manner and improve the recognition and care of childhood asthma in practice.

Citations